- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Eylea to Treat Diabetic Retinopathy in Patients With Diabetic Macular Edema
Diabetic retinopathy affects 33% of all patients with diabetes over 40; 29 million Americans have type 1 or type 2 diabetes.
The FDA today approved the use of Eylea (afilbercept) injections to treat diabetic retinopathy in patients who have diabetic macular edema (DR), the most common diabetic eye disease and a leading cause of blindness in adults.
According to CDC, this disease affects more than 33% of adults with diabetes age 40 and older had some form of DR; with 29 million Americans suffering either type 1 or type 2 diabetes, the potential for DR is significant in the US population.
Eylea, made by Regeneron, is administered through monthly injections for 5 months, then every 2 months. It is intended to be used alongside a modified diet and other interventions to control blood sugar, blood pressure, and cholesterol.
Safety and efficacy of Eylea to treat DR patients with DME evaluated in 2 clinical trials involving 679 patients. They were randomly assigned to have Eylea or macular laser photocoagulation, a laser treatment that burns small areas of the retina. At week 100, patients with Eylea showed significant improvement over those with the laser treatments.
Common side effects were bleeding of the conjunctiva, eye pain, cataracts, floaters, increased eye pressure, and separation of the interior jelly of the eye from the retina. Serious event included retinal detachments and infections within the eye.
Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes
November 19th 2024Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
